Addiction is the most stigmatized medical condition in America. It is also one of the most misunderstood. The persistent belief that addiction is a choice, a character flaw, or a moral failure — rather than a chronic brain disorder — is not just inaccurate. It is clinically harmful: it delays treatment, generates shame that drives continued use, and sustains a healthcare system that treats addiction as a consequence rather than a condition. This article explains what addiction actually is — clinically, neurologically, and practically.
Understanding Addiction Is the First Step — We Can Help With the Rest
Same-day clinical assessments. Evidence-based treatment. In-network with major insurance. Call 770-573-9546.
The Clinical Definition
The American Society of Addiction Medicine (ASAM) defines addiction as “a treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the environment, and an individual’s life experiences.” The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classifies substance use disorders — the clinical term for addiction — using 11 specific criteria across four domains: impaired control over use, social impairment, risky use, and pharmacological indicators (tolerance and withdrawal).
Meeting 2 to 3 criteria defines mild substance use disorder. Meeting 4 to 5 defines moderate. Meeting 6 or more defines severe. The diagnosis is categorical and dimensional — it exists on a spectrum from mild to severe, and it is defined by clinical criteria, not by the particular substance involved, the quantity used, or the demographic characteristics of the person using it.
What Happens in the Brain
The neurological changes of addiction are among the best-documented phenomena in behavioral medicine. The mechanism centers on dopamine — the neurotransmitter most centrally involved in reward, motivation, and learning — and the brain’s mesolimbic reward pathway, which runs from the ventral tegmental area to the nucleus accumbens (often called the brain’s “reward center”).
When a person uses an addictive substance, dopamine is released in the nucleus accumbens at levels far exceeding what natural rewards (food, sex, social connection, achievement) produce. The brain interprets this dopamine signal as evidence of something profoundly important — something to remember, to seek again, to prioritize above other activities. The addictive substance essentially hijacks the brain’s survival-level priority system, encoding itself as a necessity rather than a pleasure.
With repeated use, the brain adapts to the excessive dopamine stimulation by reducing receptor density and sensitivity — downregulation. The practical consequence: natural rewards become less pleasurable (anhedonia), the substance is needed at higher doses to produce the same effect (tolerance), and the absence of the substance produces a depleted dopamine state that feels unbearable (withdrawal). The person is no longer using primarily to feel good. They are using to feel normal.
Why Willpower Alone Fails
The prefrontal cortex — the brain region responsible for impulse control, long-term planning, evaluation of consequences, and the ability to override immediate reward in favor of future goals — is demonstrably impaired in addiction. Neuroimaging studies consistently show reduced prefrontal cortex activity and gray matter volume in people with severe substance use disorders. This is not a character trait. It is a measurable neurological change.
The practical implication: the very brain region that would allow a person to consistently choose long-term recovery over immediate use is the one most compromised by the addiction. Telling someone with severe SUD to “just choose to stop” is similar to telling someone with a broken leg to “just choose to walk normally.” The mechanism that would enable the choice is impaired. This is the neurological rationale for evidence-based treatment — it addresses the mechanisms that willpower cannot.
Genetics and Risk
Addiction has a strong genetic component. Research in twin studies estimates heritability of addiction at approximately 40 to 60 percent across substances — meaning genetic factors account for about half of the variance in addiction risk. Family history of addiction significantly increases individual risk. This genetic contribution operates through multiple mechanisms: differences in dopamine receptor density, differences in the rewarding effects of substances at initial use, differences in stress reactivity, and differences in impulsivity and executive function.
Genetic risk is not genetic destiny. A person with a family history of addiction who never uses a substance will not develop addiction. Genetic risk interacts with environmental exposures, life experiences, trauma history, and access to substances. But the genetic component explains why addiction “runs in families” and why the moralistic framing of addiction as purely a choice is biologically inaccurate.
Trauma and Addiction — The Connection
Adverse childhood experiences (ACEs) — including physical abuse, sexual abuse, emotional neglect, witnessing domestic violence, parental substance use, and household dysfunction — dramatically increase the risk of developing substance use disorder in adulthood. The ACE Study (one of the largest investigations of childhood adversity ever conducted) showed a graded relationship between the number of ACEs and the risk of addiction: people with 4 or more ACEs have a 7 to 10 times higher risk of developing alcohol use disorder than people with no ACEs.
The mechanism involves multiple pathways: early trauma disrupts the developing stress response system, making the person more reactive to stress and more vulnerable to the stress-buffering effects of substances. Trauma also produces PTSD symptoms — intrusion, hypervigilance, emotional numbness — that substances often temporarily relieve. Many people with addiction are, at the most fundamental level, managing untreated trauma. This is why trauma-focused treatment — particularly EMDR, which directly processes traumatic memories — is a core component of evidence-based addiction care.
What Evidence-Based Treatment Actually Does
Evidence-based addiction treatment works by addressing the neurobiological, psychological, behavioral, and social dimensions of addiction simultaneously. Medication-Assisted Treatment (MAT) with buprenorphine addresses the opioid receptor dysfunction and dopamine system disruption that drives opioid use disorder — it is medicine that treats a medical condition, not a substitute addiction. Cognitive Behavioral Therapy (CBT) addresses the automatic thought patterns and behavioral sequences that sustain use — the cues, triggers, and responses that operate below the level of conscious deliberate choice. Contingency Management leverages the dopamine reward system to rebuild sensitivity to non-drug rewards. EMDR for trauma addresses the underlying trauma that drives self-medication. Dual diagnosis treatment simultaneously addresses co-occurring mental health conditions that sustain addiction and are sustained by it.
The combination of these approaches — tailored to the individual’s specific neurobiological, psychological, and social situation — is what produces the outcomes that willpower and moral resolve alone cannot. Treatment does not cure addiction. It manages a chronic condition in the same way that insulin management and dietary change manage diabetes — by providing the tools, the structure, and the ongoing support that the condition requires.
Is Addiction a Disease?
The “addiction as disease” framing is both clinically accurate and politically contested. It is accurate in the specific sense that addiction involves measurable neurobiological changes, has a genetic component, responds to evidence-based medical treatment, and follows a chronic relapsing course that is not explained by voluntary choice alone. These are the defining characteristics of medical disease, and addiction meets them.
The disease framing is contested by people who believe it removes personal responsibility. But medical disease and personal agency are not mutually exclusive — people with Type 2 diabetes are responsible for their dietary choices even though diabetes has a biological basis. People with addiction bear responsibility for the choices they make in recovery even though the addiction has a neurobiological basis. The disease framework does not eliminate agency — it contextualizes it within a biological reality that willpower alone cannot fully override.
The Most Important Thing to Understand
Addiction is treatable. Not curable — manageable, like other chronic conditions. But the outcomes of evidence-based treatment are compelling: MAT for opioid use disorder reduces overdose mortality by more than 50%. Long-term AA/NA participation is associated with significantly higher rates of sustained sobriety than no treatment. CBT and contingency management produce measurable reductions in substance use across multiple populations. The evidence for effective addiction treatment is as strong as the evidence for treatment of many other chronic conditions — stronger than the evidence for some treatments considered mainstream in other specialties.
What stands between most people with addiction and effective treatment is not the absence of effective treatment. It is stigma, access, misinformation, and delay. This article is one small effort to address the misinformation piece. The access piece is what we work on every day at Hope Harbor Wellness.
Evidence-Based Addiction Treatment Near Atlanta, GA
Hope Harbor Wellness · 126 Enterprise Path, Suite 208, Hiram, GA 30141 · PHP, IOP, MAT, Dual Diagnosis · 770-573-9546
Frequently Asked Questions — What Is Addiction?
Is addiction a choice or a disease?
It is both, in a meaningful sense — and neither, in an oversimplified sense. Addiction involves neurobiological changes that are measurable, heritable, and not fully controllable by willpower. It also involves behavioral choices, particularly early in use. Over time, as the neurobiological changes deepen, the choice dimension shrinks and the compulsive dimension grows. The disease framing is clinically accurate and does not eliminate personal responsibility — it contextualizes it within a biological reality.
Why can some people use drugs or alcohol recreationally without becoming addicted?
Genetic variability in dopamine receptor density, differences in the rewarding response to substances at first use, differences in stress reactivity, and differences in trauma exposure all contribute to variable addiction risk across individuals. Some people have significantly lower genetic risk. Some people’s reward systems respond less intensely to substance-induced dopamine release. Addiction risk is distributed across a population, not uniform.
Can addiction be cured?
Addiction is not typically described as curable in the way that a bacterial infection is cured. It is a chronic condition that can be effectively managed, with many people achieving sustained remission — years or decades of sobriety with minimal craving or impairment. MAT for opioid use disorder may need to be maintained long-term, similar to how insulin management of diabetes requires ongoing treatment. The goal is not cure but effective, sustained management that allows a full life.
How does MAT (Suboxone) treat addiction rather than just replacing one addiction with another?
Buprenorphine (Suboxone) is a medication that stabilizes opioid receptor function, eliminates withdrawal, reduces craving, and dramatically reduces overdose mortality. Untreated opioid use disorder has a very high mortality rate. Calling buprenorphine treatment “addiction substitution” is like calling insulin treatment “sugar substitution” — it misunderstands what both the disease and the treatment are actually doing. Buprenorphine is medicine. It treats a medical condition.
